Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MHRA

UCB trials wearable sensor for Parkinson’s

Its medical device combines with a mobile app to measure motor symptom patterns

- PMLiVE

UCB appoints new managing director of Britain and Ireland

Steve Turley joins from Lundbeck

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

- PMLiVE

UCB staff high five for arthritis

Firm supports the World Arthritis Day social media campaign

- PMLiVE

Novartis’ Cosentyx effective in psoriatic arthritis study

Further supports drugs ability to reduce progression of damage to joints

- PMLiVE

UK patients offered app to report adverse reactions

Yellow Card app allows potential side-effects tobe sent directly to the MHRA

- PMLiVE

New health ministers and re-appointments after reshuffle

Industry sees both continuity and change after the UK’s General Election

- PMLiVE

Celgene’s psoriasis pill gives ‘no added benefit’ to patients

Germany’s cost assessor IQWiG says Otezla is not value for money

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

- PMLiVE

Dr. Reddy’s enters €118m product agreement with UCB in India

Portfolio acquisition will expand firm’s therapy footprint

- PMLiVE

UCB and MRC join forces on novel antibody discovery platform

Will provide UK scientists with access to up-to-date technologies

- PMLiVE

Novartis cancer pill makes it onto UK early access list

Joins Merck’s melanoma drug Keytruda for the MHRA’s accelerated review programme 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links